Clinical Trial Update: A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of HCP1803 compared with RLD2001-1 in essential hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• HCP1803
• RLD2001-1

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hypertension | Phase 3 | Status: COMPLETED